DOSEGUY

Eloralintide

weak data

Also seen as: LY3841136

The Dose Guy’s verdict
Sep 1, 2026
3 sources

Eloralintide is the strongest amylin-pathway result to date, solo, no GLP-1 in the mix. That puts it in the same weight class as the incretins through a different mechanism, and Lilly is clearly building toward combination trials. But eloralintide is still a clinical-stage compound with no approval, limited gray-market availability, and no long-term safety data. If you want amylin now, cagrilintide is the one you can actually get. Eloralintide is the next version of that idea, and the right move is to let the trials finish.

Would I take it?Caution, one to watch, not to run.

What it is

A long-acting amylin receptor agonist, built by Eli Lilly for once-weekly subcutaneous injection. Amylin is the hormone your pancreas co-releases with insulin after a meal. It slows gastric emptying, suppresses glucagon, and sends a strong satiety signal, a different appetite pathway from the GLP-1 drugs that dominate this shelf. Cagrilintide proved the amylin concept could produce real weight loss. Eloralintide is the next iteration: more selective for the AMY1 receptor subtype, designed to hit harder with less nausea, and built for weekly dosing from the start.

Eloralintide is not a competitor to retatrutide or tirzepatide as a solo agent for pure weight loss. Its future is as a combination partner, the amylin arm added to an incretin backbone, the way CagriSema pairs cagrilintide with semaglutide. Lilly has not announced the pairing trials yet, but the program points that direction.

What the research shows

The evidence is early but real: one phase 1, one phase 2, and a network meta-analysis that puts eloralintide in context.

At 48 weeks, mean body-weight loss was 20% with eloralintide 9 mg and 20% with the 6-to-9 mg escalation arm, versus 0.4% with placebo.Lancet 2025 · phase 2 · n=263 · 48wk
At 12 weeks, body-weight reductions ranged from 2.6% to 11.3% across eloralintide dose groups in the multiple-dose trial.Diabetes Obes Metab 2026 · phase 1 · n=100 · 12wk
A network meta-analysis estimated high-dose eloralintide at 18.01% weight loss versus placebo, ranking second among amylin-based therapies with a P score of 0.89.Endocrinol Diabetes Metab 2026 · NMA · 6 trials · n=4642

Realistic protocols

Eloralintide is a clinical-stage investigational compound. It is not approved, not commercially available, and not widely circulating on the gray market as of mid-2026. The trial protocol used once-weekly subcutaneous injection with dose-escalation arms up to 9 mg. I am describing the trial design, not recommending a protocol.

If the amylin pathway is what interests you, cagrilintide is available now and pairs well with an incretin at small weekly doses. Eloralintide may eventually replace it as the stronger, cleaner version. Today, cagrilintide is the amylin mechanism you can actually use.

Side effects

Phase 1 and phase 2 side effects track the amylin class, with dose-dependent GI and fatigue signals:

commonNausea, strongly dose-dependent. Mild and comparable to placebo at the lower trial doses, frequent at the higher ones.
commonFatigue, strongly dose-dependent: 43% at 9 mg and 46% on the 6-to-9 mg arm versus 12% on placebo. This is not mild.
commonDecreased appetite, the mechanism working as intended.
unknownNo long-term safety data beyond 48 weeks. The amylin pathway is understood from cagrilintide, but eloralintide is a different molecule and its own safety profile is still being drawn.

Where to buy

Disguised Research–
$179.99 / unit
⚠ ⚠ Unreachable since Sep 11
✓ verified Sep 8
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.